{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=28",
    "query": {
      "intervention": "Open Label Extension Study",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 2082,
    "total_pages": 209,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=29&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=27&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T21:51:30.550Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05889273",
      "title": "ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "ML-004 (IR)/(ER) tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MapLight Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "46 Years",
        "sex": "ALL",
        "summary": "12 Years to 46 Years"
      },
      "enrollment_count": 120,
      "start_date": "2023-06-01",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-10-31T21:51:30.550Z",
      "location_count": 18,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Glendale, California + 15 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Rafael",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05889273"
    },
    {
      "nct_id": "NCT01962922",
      "title": "Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Failure"
      ],
      "interventions": [
        {
          "name": "LCP-Tacro",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus -IR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veloxis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 50,
      "start_date": "2013-11",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2018-06-06",
      "last_synced_at": "2026-10-31T21:51:30.550Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • St Louis, Missouri • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01962922"
    },
    {
      "nct_id": "NCT01691859",
      "title": "MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Mepolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 347,
      "start_date": "2012-09-28",
      "completion_date": "2017-05-31",
      "has_results": true,
      "last_update_posted_date": "2023-06-28",
      "last_synced_at": "2026-10-31T21:51:30.550Z",
      "location_count": 11,
      "location_summary": "Long Beach, California • Riverside, California • Denver, Colorado + 8 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Albany",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01691859"
    },
    {
      "nct_id": "NCT03714373",
      "title": "Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prader-Willi Syndrome"
      ],
      "interventions": [
        {
          "name": "DCCR",
          "type": "DRUG"
        },
        {
          "name": "Placebo for DCCR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Soleno Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2018-10-01",
      "completion_date": "2023-08-17",
      "has_results": false,
      "last_update_posted_date": "2024-04-19",
      "last_synced_at": "2026-10-31T21:51:30.550Z",
      "location_count": 20,
      "location_summary": "Orange, California • Palo Alto, California • San Diego, California + 17 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03714373"
    },
    {
      "nct_id": "NCT06436183",
      "title": "A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atopic Dermatitis",
        "Atopic",
        "Dermatitis",
        "Dermatologic Disease",
        "Eczema",
        "Eczema Atopic Dermatitis",
        "Eczema, Atopic"
      ],
      "interventions": [
        {
          "name": "Camoteskimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Apollo Therapeutics Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 62,
      "start_date": "2024-05-01",
      "completion_date": "2025-08-12",
      "has_results": false,
      "last_update_posted_date": "2025-09-18",
      "last_synced_at": "2026-10-31T21:51:30.550Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Encinitas, California • Fountain Valley, California + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06436183"
    },
    {
      "nct_id": "NCT02842086",
      "title": "Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pre-Exposure Prophylaxis of HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "F/TAF",
          "type": "DRUG"
        },
        {
          "name": "F/TDF",
          "type": "DRUG"
        },
        {
          "name": "F/TAF Placebo",
          "type": "DRUG"
        },
        {
          "name": "F/TDF Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5399,
      "start_date": "2016-09-02",
      "completion_date": "2026-07-29",
      "has_results": true,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-10-31T21:51:30.550Z",
      "location_count": 54,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Newport Beach, California + 38 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02842086"
    },
    {
      "nct_id": "NCT01592773",
      "title": "Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder (ASD)",
        "Autism",
        "Autistic Disorder",
        "Asperger's Disorder",
        "Asperger's",
        "Pediatric Autism",
        "Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)"
      ],
      "interventions": [
        {
          "name": "Memantine Hydrochloride (HCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "6 Years to 12 Years"
      },
      "enrollment_count": 747,
      "start_date": "2012-10",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2015-02-16",
      "last_synced_at": "2026-10-31T21:51:30.550Z",
      "location_count": 68,
      "location_summary": "Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01592773"
    },
    {
      "nct_id": "NCT07811362",
      "title": "CRPS-RISE Outcomes Registry",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Complex Regional Pain Syndrome I (CRPS I)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ambros Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 270,
      "start_date": "2026-09-17",
      "completion_date": "2029-04-16",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-31T21:51:30.550Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07811362"
    },
    {
      "nct_id": "NCT00943579",
      "title": "Open-Label Extension Study of Kuvan for Autism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Autistic Disorder"
      ],
      "interventions": [
        {
          "name": "Kuvan®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Children's Health Council",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "3 Years to 6 Years"
      },
      "enrollment_count": 41,
      "start_date": "2009-08",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2018-05-02",
      "last_synced_at": "2026-10-31T21:51:30.550Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00943579"
    },
    {
      "nct_id": "NCT03382262",
      "title": "Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteoarthritis of the Shoulder",
        "Osteoarthritis of the Hip"
      ],
      "interventions": [
        {
          "name": "FX006 32 mg",
          "type": "DRUG"
        },
        {
          "name": "TAcs 40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pacira Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2017-12-18",
      "completion_date": "2018-10-09",
      "has_results": true,
      "last_update_posted_date": "2024-01-24",
      "last_synced_at": "2026-10-31T21:51:30.550Z",
      "location_count": 6,
      "location_summary": "El Cajon, California • La Mesa, California • San Diego, California + 3 more",
      "locations": [
        {
          "city": "El Cajon",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03382262"
    }
  ]
}